There are approximately 300,000–350,000 cases of out-of-hospital sudden cardiac arrest (SCA) or sudden cardiac death in the USA yearly, imparting a substantial public health burden.

Factors that have been most commonly associated with the occurrence of SCA in the overall population include coronary artery disease and associated markers such as diabetes mellitus, left ventricular hypertrophy (LVH), hyperlipidemia, and cardiomyopathies. However, little is known about the association between anemia and the development of SCA in the general population. QT prolongation and LVH are risk factors of ventricular fibrillation. However, it is not known whether the severity of anemia is related to QT prolongation and LVH. The aim of this study was to assess the effect of anemia on SCA in a general population by using a national database.

Anemia is common in patients with cardiovascular disease and is a multifactorial problem, especially in the elderly population. The risks of mortality, morbidity and hospitalization in patients with anemia were similar to those of 4 other common cardiovascular risk factors: smoking, diabetes mellitus, arterial hypertension, and hypercholesterolemia. Consequently, anemia has lately been characterized as “the fifth cardiovascular risk factor.” Anemia is present in one-third of patients with acute coronary syndrome (ACS); in particular, in 12.8% of patients with acute myocardial infarction (MI), in 43% of the elderly patients with ST-elevation MI and in 5–10% of non-ST-elevation ACS patients. Recently, it was reported that anemia is associated with increased mortality and sudden death in patients with diastolic heart failure (HF).

There are approximately 300,000–350,000 cases of out-of-hospital sudden cardiac arrest (SCA) or sudden cardiac death in the USA yearly, imparting a substantial public health burden. Factors that have been most commonly associated with the occurrence of SCA in the overall population include coronary artery disease and associated markers such as diabetes mellitus, left ventricular hypertrophy (LVH), hyperlipidemia, and cardiomyopathies.

However, little is known about the association between anemia and the development of SCA in the general population. QT prolongation and LVH are risk factors of ventricular fibrillation. However, it is not known whether the severity of anemia is related to QT prolongation and LVH. The aim of this study was to assess the effect of anemia on SCA in a general population by using a national database.

**Background:** The relationship between anemia and sudden cardiac arrest (SCA) is unclear in the general population, so we assessed it in a nationwide cohort.

**Methods and Results:** We studied 494,948 subjects (mean age, 47.8 years; 245,333 men [49.6%]) with national health check-up data from the Korean National Health Insurance Database Cohort. During a mean follow-up period of 5.4 years, SCA occurred in 616 participants (396 men, 220 women). The incidence rates of SCA increased across the 4 anemia groups in both men (0.3, 1.5, 5.3, and 4.5 per 1,000 person-years) and women (0.2, 0.5, 0.5, and 1.2 per 1,000 person-years). The SCA risk per 1-unit decrease in hemoglobin (Hb) increased by 21% and 24%, respectively, in multivariable models adjusted for cardiovascular factors, in men (95% confidence interval [CI], 13–29%; \( P<0.001 \)) and women (95% CI, 13–37%; \( P<0.001 \)). A negative correlation between QTc interval and Hb level was observed in men, and a trend was observed in women.

**Conclusions:** Anemia was associated with an increased risk of SCA even after accounting for concomitant conditions in a South Korean nationwide cohort. The correlation between anemia and SCA might be explained by an increase in arrhythmic risks, such as QTc prolongation.

**Key Words:** Anemia; General population; Sudden cardiac arrest
Methods

Source of Study Data

A national health insurance system in Korea was established in 1963 according to the National Health Insurance Act, and it is compulsory for all citizens in South Korea to participate. The National Health Insurance Service (NHIS) released the National Sample Cohort (2002–2013) database (NHIS-NSC [2002–2013]) in 2015. It consists of 1,025,340 Koreans as an initial 2002 cohort and followed up the subjects through 2013. The national cohort represents approximately 2.2% of the source population in 2002 (46,605,433). This is a semi-dynamic cohort database; namely, the cohort was followed up to either the time of the participant’s disqualification from health services because of death or emigration, or the end of the study period. The national cohort contains eligibility and demographic information about health insurance and medical aid beneficiaries, medical bill details, medical treatment, disease histories, and prescriptions; such data are constructed after converting insurance claim information to the first day of medical treatment.

In the cohort, the subjects’ disease information was classified according to the 10th revision of the International Classification of Diseases (ICD-10) codes, and the subjects’ mortality data, as well as the cause of death, were obtained from the Korean National Statistical Office. As this study was based on data from the NHIS, informed consent was not specifically obtained individually. Data were fully anonymized and de-identified for the analysis. This study was approved by the Institutional Review Board of Severance Hospital.

Study Population

A total of 506,805 subjects had a nationwide health examination after 2009. However, 11,857 were excluded because of missing data in variables of the health examination. Finally, this study included 494,948 subjects older than 18 years, who had had a physical examination in 2009 and had follow-up data until December 2013 (Figure 1).

To ensure diagnostic accuracy, we defined patients with comorbidities, including hypertension, diabetes mellitus, and HF, only when the condition was a discharge diagnosis or confirmed more than twice in the outpatient department. Furthermore, the laboratory and survey questionnaire data of general and life-transition health examinations for all cohort members were merged.

Anemia was analyzed as both a continuous and a categorical variable. According to the World Health Organization criteria, anemia is defined as a hemoglobin (Hb) concentration <13 g/dL in men and <12 g/dL in women. We also defined mild anemia as an Hb concentration of 11 to <13 for men and 11 to <12 for women, moderate anemia as Hb 8 to <11 g/dL, and severe anemia as Hb <8 g/dL.

At the time of Hb measurement, systolic and diastolic pressures were also measured; serum samples for fasting glucose, Hb, and total cholesterol levels were also obtained after an overnight fast at each examination site. Detailed histories of smoking status, alcohol consumption, and physical activity (including amount and frequency) were obtained through questionnaires.

To evaluate the relationships between anemia and ECG parameters, including QT, QTc intervals (corrected QT interval), T-wave abnormality, and LVH, additional analyses were performed using the MUSE system in 11,782 individuals who were admitted to Severance Hospital from 2004 to 2009. QTc prolongation was defined as >450 ms in men and >470 ms in women. The study protocol was approval by the Institutional Review Board of Severance Hospital and complied with the Declaration of Helsinki.

Definition and Validation of SCA

In the NHIS-NSC, the cause of deaths was coded using the
ICD-10 codes. We identified 1,001 patients (men 651, women 350) with SCA and ICD-10 codes I46.x (cardiac arrest) and I49.0 (ventricular fibrillation). To exclude patients with non-cardiac arrest, we excluded 385 patients (men 255, women 130) with a diagnosis of SCA accompanied by respiratory arrest (R09.0, R09.2), gastrointestinal bleeding (I85.0, K25.0, K25.4, K26.0, K26.4, K27.0, K27.4, K92.0–K92.2), brain hemorrhage (I60.x–I62.x, S06.4–S06.6), septic shock (A41.9, R57.2), pregnancy and delivery (O00–O99), diabetic ketoacidosis (E14.1), anaphylaxis (T78.2), and accidents including asphyxiation, drowning, bleeding (I85.0, K25.0, K25.4, K26.0, K26.4, K27.0, K27.4, K27.8), and others (0.9%).

### Statistical Analysis

The baseline characteristics of the 2 groups were compared by Student’s t-test for continuous variables, and by chi-square test or Fisher’s exact test for categorical variables. The matched patient groups were compared by paired t-test for continuous variables and by McNemar’s test for categorical variables. We used a sex-specific Kaplan-Meier plot for the presentation of survival curves in the anemia group and a log-rank test to assess whether the survival curves were statistically significantly different. To investigate the association between anemia or anemia category and the risk of SCA, we used a sex-specific Cox’s proportional hazard regression model with adjustment for clinical variables including age, body mass index, chronic kidney disease, end-stage renal disease, and cancer (T1, T1.1, T1.2–T1.6, V01–V99, W00–99, X60–X84) (Figure 1).

To evaluate the accuracy of our definition of SCA, we conducted a validation study with the medical records of 2 independent tertiary hospitals from 2009 to 2013. We found 731 patients with code I46.x or I49.0 after excluding those with diagnostic codes for non-cardiac causes as mentioned before. Their medical records were then reviewed by 5 physicians, and we ascertained the patients with true SCA. The positive predictive value was 80.2% (586 of 731) using our criteria of SCA, suggesting good diagnostic accuracy of our definition. False-positive cases were respiratory arrest (7.0%), history of SCA (4.2%), arrest caused by cancer progression (1.9%), accidents (1.8%), bleeding (1.8%), metabolic acidosis (1.0%), septic shock (0.8%), stroke (0.5%), and others (0.9%).
Anemia and SCA

Anemia and SCA

Incidence of SCA

During a mean follow-up of 5.4 years, 616 participants (men 396, women 220) had a SCA. Demographics of participants with SCA are presented in Table S1. Of the 616 participants, 181 (29.7%) were anemic. A total of 92 (23.2%) men and 89 (40.5%) women had anemia. Before developing SCA, 930 men and 364 women had experienced MI, and 1,513 men and 1,384 women had experienced HF.

During the follow-up period, 6,219 participants (4,003 men, 2,216 women) died.

The age-adjusted incidence rates of SCA are presented categories. We studied whether anemia predisposed patients to SCA through an interim MI or HF event. We used a linear-by-linear association trend test for the calculation of the rates of QTc prolongation and LVH, as well as T-wave abnormality according to the severity of anemia. All statistical analyses were performed using SPSS software version 20.0 (IBM Corp., Chicago, IL, USA). Statistical significance was established at a P<0.05.

Results

Study Subjects

The baseline characteristics of the study are presented in Table 1. The mean age was 47.8 (range, 18–98) years in men and 47.8 (range, 18–98) years in women. Of the 494,948 participants, 59,565 (12.0%) were anemic, including 42,185, 16,323, and 1,057 with mild, moderate, and severe anemia, respectively; 12,932 (5.3%) men and 46,633 (18.8%) women had anemia. Anemia was more common in women than in men (P<0.001). Participants with anemia were older, and more frequently had comorbidities than those without anemia.

Incidence of SCA

During a mean follow-up of 5.4 years, 616 participants (men 396, women 220) had a SCA. Demographics of participants with SCA are presented in Table S1. Of the 616 participants, 181 (29.7%) were anemic. A total of 92 (23.2%) men and 89 (40.5%) women had anemia. Before developing SCA, 930 men and 364 women had experienced MI, and 1,513 men and 1,384 women had experienced HF. During the follow-up period, 6,219 participants (4,003 men, 2,216 women) died.

The age-adjusted incidence rates of SCA are presented

Table 2. Hb and the Risk of Sudden Cardiac Arrest (Multivariable Models)

| Model                                      | Men                        | Women                     |
|--------------------------------------------|----------------------------|---------------------------|
| With Hb as a continuous variable (per 1 g/dL decrease) | HR (95% CI) | P value | HR (95% CI) | P value |
| Age adjusted                               | 1.26 (1.18–1.35)           | <0.001                    | 1.32 (1.20–1.45) | <0.001 |
| Adjusted for clinical variables†           | 1.32 (1.13–1.29)           | <0.001                    | 1.25 (1.13–1.38) | <0.001 |
| Adjusted for clinical variables and interim MI, HF† | 1.21 (1.13–1.29) | <0.001                    | 1.24 (1.13–1.37) | <0.001 |
| With anemia as a categorical variable*     |                           |                           |                           |
| None                                       |                             | 1                         |                             | 1          |
| Mild anemia                                | 1.50 (1.13–1.99)           | <0.001                    | 1.88 (1.37–2.59)           | <0.001     |
| Moderate anemia                            | 4.01 (2.64–6.08)           | <0.001                    | 1.86 (1.23–2.81)           | <0.001     |
| Severe anemia                              | 6.19 (1.53–25.01)          | <0.001                    | 8.77 (3.22–23.86)          | <0.001     |
| Trend across categories                    | 4.25 (1.03–17.65)          | 0.05                      | 5.77 (2.03–16.36)          | <0.001     |

The Hb categories are as follows: normal, ≥13 g/dL for men and ≥12 g/dL for women; mild anemia, 11 to <13 g/dL for men and 11 to <12 g/dL for women; moderate anemia, 8 to <11 g/dL; and severe anemia, <8 g/dL. *Adjusted for clinical variables including age, BMI, CKD or ESRD, COPD, diabetes mellitus, dyslipidemia, hypertension, HF, interim MI and HF, malignancy, previous MI, previous ischemic stroke, regular use of cigarettes in the prior year. CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1.
in Table 1. The incidence rates of SCA increased across the categories of anemia in men (0.3, 1.5, 5.3, and 4.5 per 1,000 person-years) and women (0.2, 0.5, 0.5, and 1.2 per 1,000 person-years), respectively. Figure 2 shows the Kaplan-Meier curves for SCA in patients with different categories of anemia. The probability of developing SCA over time increased across the categories of anemia.

Risk of SCA According to Anemia
The results of the multivariable Cox’s proportional hazard regression are shown in Table 2. After adjustment for age alone, each 1-unit decrease in Hb was associated with an increase of 26% for men (P<0.001) and 32% for women (P<0.001). These relations remained significant in the multivariable-adjusted models, with an increase in the risk of SCA per 1-unit decrease in Hb of 32% for men (P<0.001) and 25% for women (P<0.001). Similarly, the age-adjusted and fully adjusted hazard ratios (HRs) for SCA increased across Hb categories in both men and women (Table 2). The multivariable-adjusted HRs for SCA were 1.50 (95% confidence interval [CI], 1.13–1.99) for mildly anemic men and 1.88 (95% CI, 1.36–2.59) for mildly anemic women. These findings were not attenuated in models adjusting for interim MI or HF in addition to baseline covariates. Each 1-unit decrease in Hb was associated with an increase of 21% for men (P<0.001) and 24% for women (P<0.001).

The association between Hb and the risk of SCA did not vary by age, sex, or systolic blood pressure (P>0.10 for all interaction terms). To assess the influence of different degrees of anemia, we estimated regressions with 4 Hb categories (normal, mild, moderate, and severe anemia). The respective age-adjusted HRs for SCA increased progressively across the 4 Hb categories in men (1.00, 1.72 [95% CI, 1.30–2.28], 5.33 [95% CI, 3.53–8.03], 5.82 [95% CI, 1.45–23.41]; P=0.001 for trend) and women (1.00, 2.04 [95% CI, 1.48–2.80], 2.35 [95% CI, 1.57–3.52], 10.10 [95% CI, 3.73–27.34]; P=0.001 for trend). After adjustment for clinical variables and interim MI or HF, these findings remained significant in men (1.00, 1.50 [95% CI, 1.13–1.99], 4.01 [95% CI, 2.64–6.08], 6.19 [95% CI, 1.53–25.01]; P=0.001 for trend) and women (1.00, 1.88 [95% CI, 1.37–2.59], 1.86 [95% CI, 1.23–2.81], 8.77 [95% CI, 3.22–23.86]; P=0.001 for trend).

In a secondary analysis restricted to mild-moderate anemia, the association between anemia and the risk of SCA remained significant (sex-pooled multivariable-adjusted HR per 1-unit increase in Hb, 1.50 [95% CI, 1.34–1.67]; P=0.001). Additionally, the relationship between anemia and the risk of SCA in the female population is presented in Figure 3. Adjusted HRs significantly increased in premenopausal women (3.83 [95% CI, 1.34–10.93, P=0.012]). Adjusted HRs for SCA also significantly increased in patients without hypertension (2.05 [95% CI, 1.24–3.34, P=0.005]), diabetes mellitus (1.96 [95% CI, 1.37–2.81, P<0.001]), chronic kidney disease or end-stage renal disease (2.26 [95% CI, 1.60–3.19, P<0.001]), and malignancy (1.98 [95% CI, 1.46–2.69, P<0.001]) and severe anemia (1.88 [95% CI, 1.42–2.50, P<0.001]), respectively.

ECG Changes Associated With Anemia
The relationship between anemia and QTc prolongation was evaluated in 11,782 individuals (mean age: 61.2±14.4 years; 6,151 [52.2%] women), who were admitted to Severance Hospital between 2004 and 2009. Their characteristics are presented in Table 3. The overall rate of QTc
Anemia and SCA

The prevalence of QTC prolongation, T-wave abnormality and LVH did not differ among microcytic, normocytic and macrocytic anemia in either men or women (Table S2).

### Discussion

The National Health Insurance Database Cohort-based data indicate that anemia is a risk factor for SCA. The association of anemia with the subsequent development of SCA persists even after accounting for concomitant conditions such as hypertension, diabetes mellitus, and MI. The validity of our results is supported by the large sample size and their consistency in multiple analyses adjusting for known confounders in men and women. Finally, our findings have biological plausibility because QTC prolongation and LVH, which are associated with SCA, increased with the severity of anemia.

### Table 3. Characteristics of the Study Population by Severity of Anemia

| Characteristic                  | None (n=7,056) | Mild anemia (n=2,214) | Moderate anemia (n=2,122) | Severe anemia (n=390) | P value |
|--------------------------------|---------------|-----------------------|---------------------------|-----------------------|---------|
| Age, years                     | 60.4±14.3     | 63.6±13.7             | 62.2±14.9                 | 57.9±17.1             | <0.001  |
| Hb, g/dL                       | 14.0±1.3      | 11.8±0.5              | 9.8±0.8                   | 6.7±1.1               | <0.001  |
| MCV, fL                        | 91.6±4.9      | 91.8±6.3              | 90.8±7.7                  | 88.3±11.9             | <0.001  |
| Serum iron, μg/dL              | 61.6±59.5     | 60.1±50.1             | 57.4±52.0                 | 65.1±95.7             | 0.13    |
| TIBC, μg/dL                    | 228.3±89.2    | 226.3±81.2            | 229.9±81.6                | 259.9±135.5           | <0.001  |
| Ferritin, ng/mL                | 693.5±2,209.7 | 602.9±2,091.5         | 498.3±1,429.2             | 876.3±3,429.8         | 0.01    |
| QTc, ms                        | 443.8±25.1    | 444.9±25.0            | 446.4±24.5                | 447.7±25.9            | <0.001  |

**p value**

Continuous variables are expressed as mean±standard deviation. Numbers in parenthesis are percentage value. MCV defined as follows: microcytic, <80 fL; normocytic, 80 to ≤100 fL; macrocytic, >100 fL. fL indicates femtoliters (10⁻15). LVH, left ventricular hypertrophy; MCV, mean cell volume; QTc, corrected QT interval; TIBC, total iron binding capacity.

### Figure 4. Correlation between QTc interval and hemoglobin (Hb) concentration in men (A) and women (B).
to a significant risk of cardiovascular death in patients with ACS. However, it is also worth mentioning that Hb >17 g/dL confers very serious risks. The frequency of anemia is constantly increasing in HF. It is estimated that anemia is present in approximately 9.0–15.6% of patients with HF in the USA. Moreover, the prevalence of anemia increases with worsening functional class, from 9% for New York Heart Association (NYHA) class I to 79% for NYHA class IV. Anemia is considered an independent risk factor for LV dysfunction and is associated with increased risks of morbidity and mortality. However, the association between SCA and anemia has not been revealed. This study showed that anemia was an independent risk factor of SCA even after accounting for concomitant conditions such MI and HF. However, further studies are needed to verify the associations and proper mechanisms between anemia and SCA.

**ECG Change by Anemia**

In this study, the QTc interval increased with the severity of anemia. Anemia is associated with increased inflammation markers and aggravated oxidative stress condition. Notably, oxidative stress in cardiomyocytes has been shown to activate Ca²⁺/calmodulin-dependent protein kinase II, sequentially inducing the prolongation of the APD and QT intervals. Moreover, reduced Hb concentration is associated with impaired oxygen delivery, salt and water retention, and chronic volume overload. However, the negative correlation between QTc prolongation and Hb was weak in women. This might be related to a sex difference in the definition of QTc prolongation. Second, compared with men, women had low hematomit and hypochromic states related to menstruation. These chronic anemic conditions might increase the increased QTc prolongation across Hb categories and decrease the statistical power in women.

**Study Limitations**

First, we identified patients with SCA by using ICD-10 codes I46.x (cardiac arrest) and I49.0 (ventricular fibrillation). SCA was confirmed by emergency medical service personnel or during hospitalization. However, we cannot exclude the possibility that some episodes of SCA were missed or overestimated. To resolve this problem, we excluded patients with SCA diagnosis accompanied by other diseases. With this method, we confirmed that the positive predictive value of our criteria of SCA was 80.2%. Moreover, such misclassification would not be expected to differentially affect persons with and without anemia. Second, we only analyzed anemia at entry in this study, and we did not consider possible changes in Hb levels during the follow-up period. Third, serum iron, ferritin, and total iron binding capacity were not available in the national cohort. Therefore, we analyzed the relationship between the type of anemia and ECG parameters using an additional hospital cohort. There was no statistically meaningful association between the type of anemia and ECG parameters. Fourth, we adjusted for multiple confounders but it is possible that residual confounding influenced the results. Finally, inherited arrhythmic disorders such as long QT syndrome, Brugada syndrome, and short QT syndrome are well-known causes of SCA. These channelopathies might be affected by anemia, which could impair cardiac autonomic function and worsen metabolic condition such metabolic acidosis, increased inflammation and aggravated oxidative stress. Thus, further studies are necessary to understand the association of anemia and inherited arrhythmic disorders that precedes SCA.

**Conclusions**

Anemia was associated with an increased risk of SCA even after accounting for concomitant conditions in a South Korean nationwide cohort. The correlation between anemia and SCA might be explained by the increase in arrhythmic risks, such as QTc prolongation.

**Sources of Funding**

This study was supported in part by research grants from the Basic Science Research Program through the National Research Foundation of Korea, Seoul, funded by the Ministry of Education, Science, and Technology (NRF-2012R1A2A2A02045367, 2010-0021993), as well as grants from the Korean Healthcare Technology R&D project funded by the Ministry of Health & Welfare (HI12C1552, HI16C0058, HI15C1200).

**Disclosures**

The authors have no conflicts of interest to disclose.

**References**

1. Spence RK. The economic burden of anemia in heart failure. *Heart Fail Clin* 2010; 6: 373–383.
2. Kainuma Y, Suzuki M, Nishimura R, Kato H. Red cell transfusion in heart failure: a randomized, controlled trial. *N Engl J Med* 2003; 349: 692–701.
3. Tada T, Shiba N, Watanabe J, Matsuki M, Kagaya Y, Shinozaki T, et al. Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. *Int J Cardiol* 2008; 128: 419–421.
4. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden of sudden cardiac death: Multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. *J Am Coll Cardiol* 2004; 44: 1268–1275.
5. Chugh SS, Reiner K, Teodorescu C, Evanado A, Kehr E, Al Samara M, et al. Epidemiology of sudden cardiac death: Clinical and research implications. *Prog Cardiovasc Dis* 2008; 51: 213–228.
6. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980–2000. *JAMA* 2002; 288: 3008–3013.
7. Havmoeller R, Reiner K, Teodorescu C, Uy-Evanado A, Mariani R, Gunson K, et al. Low rate of secondary prevention ICDs in the general population: Multiple-year multiple-source surveillance of sudden cardiac death in the Oregon Sudden Unexpected Death Study. *J Cardiovasc Electrophysiol* 2013; 24: 60–65.
8. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: The Paris Prospective Study I. *Circulation* 1999; 99: 1978–1983.
9. Albert CM, Chae CU, Groatstein F, Rose LM, Rexrode KM, Rustin JN, et al. Propective study of sudden cardiac death among women in the United States. *Circulation* 2003; 107: 2096–2101.
10. Piva e Mattos B, Torres MA, Freitas VC, Scolari FL, Loreto MS. Ventricular arrhythmias and left ventricular hypertrophy in hypertrophic cardiomyopathy. *Arq Bras Cardiol* 2013; 100: 432–439.
11. Chao TF, Huang YC, Liu CJ, Chen SJ, Wang KL, Lin YJ, et al.
Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: A nationwide cohort study. *Heart Rhythm* 2014; 11: 1941–1947.

14. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: A Nationwide cohort study from Taiwan. *J Am Coll Cardiol* 2015; 66: 1339–1347.

15. Nutritional anemias: Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968; 405: 5–37.

16. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. *J Am Coll Cardiol* 2002. 40: 27–33.

17. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol* 2004; 44: 547–553.

18. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. *J Am Coll Cardiol* 2005; 45: 391–399.

19. Xie LH, Chen F, Karagueuzian HS, Weiss JN. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. *Circ Res* 2009; 104: 79–86.

20. McCullough PA, Lepor NE. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: Implications for prognosis and treatment. *Rev Cardiovasc Med* 2005; 6: 1–10.

21. Anemia and SCA. *Circulation Journal* Vol.82, December 2018

22. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. *J Am Coll Cardiol* 2000; 35: 1737–1744.

23. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, et al. Anemia and its relationship to clinical outcome in heart failure. *Circulation* 2004; 110: 149–154.

24. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonnizi L, et al. Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. *J Card Fail* 2005; 11: 91–98.

25. van der Zee S, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. *Nat Rev Cardiol* 2009; 6: 580–589.

26. Koveshy CP, Kalantar-Zadeh K. Biomarkers of clinical outcomes in advanced chronic kidney disease (Review article). *Nephrology (Carlton)* 2009; 14: 408–415.

27. Erickson JR, Joiner ML, Lu X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. *Cell* 2008; 135: 462–474.

28. Sozen AB, Demirel S, Akkaya V, Kudat H, Yerenal M, et al. Autonomic dysfunction in vitamin B12 deficiency: A heart rate variability study. *J Auton Nerv Syst* 1998; 71: 25–27.

29. Romero Mestre JC, Hernandez A, Agramonte O, Hernandez P. Cardiovascular autonomic dysfunction in sickle cell anemia: A heart rate variability study. *Clin Auton Res* 1997; 7: 121–125.

30. Franzoni F, Galetta F, Di Muro C, Buti G, Pentimone F, Santoro G. Heart rate variability and ventricular late potentials in beta-thalassemia major. *Haematologica* 2004; 89: 233–234.

31. Prchal JT, Crist WM, Roper M, Wellner VP. Hemolytic anemia, recurrent metabolic acidosis, and incomplete albinism associated with glutathione synthetase deficiency. *Blood* 1983; 62: 754–757.

**Supplementary Files**

**Supplementary File 1**

**Table S1.** Demographics of the study population with sudden cardiac arrest according to severity of anemia

**Table S2.** Incidence of QTc prolongation by the mean cell volume category

Please find supplementary file(s); http://dx.doi.org/10.1253/circj.CJ-18-0046